Jpmorgan Chase & CO Inmune Bio, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INMB
# of Institutions
63Shares Held
4.78MCall Options Held
80KPut Options Held
41.8K-
Black Rock Inc. New York, NY813KShares$5.08 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA628KShares$3.93 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$3.73 Million45.87% of portfolio
-
Praetorian Pr LLC Rincon, PR485KShares$3.03 Million1.57% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$2.31 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $112M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...